The Importance of Tau Phosphorylation for Neurodegenerative Diseases

Overview

Journal Front Neurol

Specialty Neurology

Date 2013 Jul 13

PMID 23847585

Citations 189

Authors

Wendy Noble

Diane P Hanger

Christopher C J Miller

Simon Lovestone

Affiliations

Soon will be listed here.

Abstract

Fibrillar deposits of highly phosphorylated tau are a key pathological feature of several neurodegenerative tauopathies including Alzheimer's disease (AD) and some frontotemporal dementias. Increasing evidence suggests that the presence of these end-stage neurofibrillary lesions do not cause neuronal loss, but rather that alterations to soluble tau proteins induce neurodegeneration. In particular, aberrant tau phosphorylation is acknowledged to be a key disease process, influencing tau structure, distribution, and function in neurons. Although typically described as a cytosolic protein that associates with microtubules and regulates axonal transport, several additional functions of tau have recently been demonstrated, including roles in DNA stabilization, and synaptic function. Most recently, studies examining the trans-synaptic spread of tau pathology in disease models have suggested a potential role for extracellular tau in cell signaling pathways intrinsic to neurodegeneration. Here we review the evidence showing that tau phosphorylation plays a key role in neurodegenerative tauopathies. We also comment on the tractability of altering phosphorylation-dependent tau functions for therapeutic intervention in AD and related disorders.

Citing Articles

Interplay between PI3k/AKT signaling and caspase pathway in Alzheimer disease: mechanism and therapeutic implications.

Bhatia V, Vikram V, Chandel A, Rattan A Inflammopharmacology. 2025; .

PMID: 40088370 DOI: 10.1007/s10787-025-01715-z.

Site-specific molecular glues for the 14-3-3/Tau pS214 protein-protein interaction reversible covalent imine tethering.

Oberheide A, van den Oetelaar M, Scheele J, Borggrafe J, Engelen S, Sattler M RSC Med Chem. 2025; .

PMID: 40070456 PMC: 11892739. DOI: 10.1039/d4md00833b.

RhoA/ROCK/GSK3β Signaling: A Keystone in Understanding Alzheimer's Disease.

Medd M, Yon J, Dong H Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996845 PMC: 11854763. DOI: 10.3390/cimb47020124.

Dehydroamino acids and their crosslinks in Alzheimer's disease aggregates.

Markovich S, Frey B, Scalf M, Shortreed M, Smith L Brain Commun. 2025; 7(1):fcaf019.

PMID: 39882022 PMC: 11775630. DOI: 10.1093/braincomms/fcaf019.

Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy.

Ahn E, Park J Cells. 2025; 14(2).

PMID: 39851517 PMC: 11764136. DOI: 10.3390/cells14020089.

References

Sergeant N, WATTEZ A, Delacourte A . Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem. 1999; 72(3):1243-9. DOI: 10.1046/j.1471-4159.1999.0721243.x. View

Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T . Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007; 25(1):81-6. DOI: 10.1111/j.1460-9568.2006.05245.x. View

Zempel H, Mandelkow E . Linking amyloid-β and tau: amyloid-β induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis. 2011; 10(1-4):64-72. DOI: 10.1159/000332816. View

Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J . Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003; 38(4):555-65. DOI: 10.1016/s0896-6273(03)00259-9. View

Caccamo A, Oddo S, Tran L, LaFerla F . Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol. 2007; 170(5):1669-75. PMC: 1854961. DOI: 10.2353/ajpath.2007.061178. View

Wang H, Brautigan D . A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2. J Biol Chem. 2002; 277(51):49605-12. DOI: 10.1074/jbc.M209335200. View

Kanaan N, Morfini G, Pigino G, LaPointe N, Andreadis A, Song Y . Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging. 2011; 33(4):826.e15-30. PMC: 3272324. DOI: 10.1016/j.neurobiolaging.2011.06.006. View

Louis J, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S . Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A. 2011; 108(17):6957-62. PMC: 3084077. DOI: 10.1073/pnas.1018777108. View

Maas T, Eidenmuller J, Brandt R . Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem. 2000; 275(21):15733-40. DOI: 10.1074/jbc.M000389200. View

10.

Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A . Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009; 70(6):922-31. View

11.

Manser C, Vagnoni A, Guillot F, Davies J, Miller C . Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity. J Neurochem. 2012; 121(3):343-8. DOI: 10.1111/j.1471-4159.2012.07650.x. View

12.

Lebouvier T, Scales T, Hanger D, Geahlen R, Lardeux B, Reynolds C . The microtubule-associated protein tau is phosphorylated by Syk. Biochim Biophys Acta. 2007; 1783(2):188-92. PMC: 2258316. DOI: 10.1016/j.bbamcr.2007.11.005. View

13.

Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow E . Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999; 38(12):3549-58. DOI: 10.1021/bi981874p. View

14.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

15.

Derkinderen P, Scales T, Hanger D, Leung K, Byers H, Ward M . Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci. 2005; 25(28):6584-93. PMC: 6725430. DOI: 10.1523/JNEUROSCI.1487-05.2005. View

16.

Killick R, Ribe E, Al-Shawi R, Malik B, Hooper C, Fernandes C . Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry. 2012; 19(1):88-98. PMC: 3873038. DOI: 10.1038/mp.2012.163. View

17.

Lee S, Wang J, Yu W, Lu B . Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated Aβ toxicity in Drosophila. Nat Commun. 2012; 3:1312. PMC: 4307937. DOI: 10.1038/ncomms2278. View

18.

Hoover B, Reed M, Su J, Penrod R, Kotilinek L, Grant M . Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010; 68(6):1067-81. PMC: 3026458. DOI: 10.1016/j.neuron.2010.11.030. View

19.

Wray S, Saxton M, Anderton B, Hanger D . Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem. 2008; 105(6):2343-52. DOI: 10.1111/j.1471-4159.2008.05321.x. View

20.

Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K . Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol. 2002; 51(6):730-9. DOI: 10.1002/ana.10222. View